The gap between the 38.2x trailing and 22.2x forward P/E suggests the consensus embeds an earnings rebound rather than paying for demonstrated output, which appears consistent with 2026Q2's 41.3% operating margin being annualized. The 13.16 PEG is unusually elevated for a staffing franchise name, implying the multiple is not being justified by modeled growth, so the valuation case rests on margin sustainability rather than expansion. Against TrueBlue (214.5x EV/EBITDA on depressed EBITDA) and Kelly (negative P/E), HQI's premium looks structural, but versus KFRC's 29.01 P/E it already carries a richer rating than a same-sector operator with higher and more consistent ROIC.

Because gross margin carries no cost of service, operating and net margin are the only meaningful measures of earning power here, and their swing from -28.6% to 41.3% within the window indicates that SG&A operating leverage, not pricing, drives reported profitability. The 33.2% net margin in 2026Q2 flatters true run-rate earning power if part of the improvement reflects the SG&A compression from $5.6M to $4.0M rather than a durable cost structure; a normalized mid-20s% net margin may be a safer underwriting assumption. Net margin also exceeding operating margin in 2026Q1 (23.9% vs 22.6%) suggests below-the-line items are material, so investors should treat adjusted earnings, rather than headline GAAP figures, as the better indicator of core franchise royalty power.

The divergence between a 41.3% operating margin and a 3.8% ROIC indicates the constraint is capital efficiency rather than profitability: with asset turnover at 0.09, roughly $93M of assets supports an annualized earnings stream that produces only low-single-digit returns on invested capital. Compared with KFRC's 18.4% ROIC and KELYA/TBI's negative returns, HQI appears to sit between structurally impaired peers and genuinely compounding ones, which suggests the equity is not yet generating returns that justify a growth-style multiple. The 2024Q3 goodwill write-down complicates the trend, since a smaller asset base mechanically flatters subsequent ROIC, so the post-impairment 1.7%-3.8% readings should be read as an improved, not deteriorating, denominator rather than proof of improving operations.

A DSO near 500-600 days alongside a DPO of just 56 days means cash is tied up on the receivable side for well over a year while payables provide almost no offsetting float, which may help explain why quarterly FCF margins swung from -12.7% to 105%. DIO and CCC are unavailable in the reported data, so working-capital efficiency cannot be summarized in a single cycle metric; analysts should instead track the DSO-DPO spread of roughly 483 days as the practical measure of the cash drag. Asset turnover at 0.07-0.09 is structurally low for a royalty model with minimal inventory, implying the asset base (including goodwill and receivables) is large relative to the $8.1M quarterly revenue it supports.

With no reported debt-to-equity figure in recent quarters and D/E having fallen from 0.26 in 2024Q1 to 0.03 in 2025Q3 before disappearing, the trend indicates voluntary deleveraging, so refinancing or covenant risk appears negligible relative to levered peers carrying D/E of 0.62-0.67. The 111.4x coverage reading should not be read as exceptional credit quality so much as a mathematical artifact of minimal interest expense, meaning coverage becomes informative only if debt is reintroduced for acquisitions or buybacks. The relevant question for investors is whether the cash freed from debt repayment is being deployed or simply accumulating against a $93.4M asset base, since idle capital would itself suppress ROIC.